Peptide Name
CJC-1295 No DAC
Updated February 2026
CJC-1295 No DAC Dosing Protocol
Comprehensive Modified GRF 1-29 protocol covering pulsatile GH dosing, reconstitution math, side effects, and comparative clinical evidence context.
Half-life
~30 minutes
Dose range
100-300 mcg per injection
Status
Research compound
Developer
Generic/non-commercial
COA-Verified Suppliers Carrying CJC-1295 No DAC
Research-grade peptide suppliers vetted for COAs, purity data, and reliability. Use code PEPPALAffiliate disclosure: some outbound supplier links are affiliate links, and we may earn a commission at no extra cost to you.
Quick Reference Card
Aliases
Modified GRF 1-29, Mod GRF 1-29, CJC-1295 without DAC
Category / Class
GH Secretagogue (GHRH Analog)
Half-Life
~30 minutes
Dosing Frequency
1-3 times daily
Dose Range
100-300 mcg per injection
Common Vial Sizes
2mg, 5mg
Route of Administration
Subcutaneous (SubQ)
Regulatory Status
Unregulated research compound (not FDA-approved)
Developer
N/A (generic research compound)
Key Stat
Preserves pulsatile GH signaling with short half-life that more closely mimics physiological GHRH release.
What Is CJC-1295 No DAC (Modified GRF 1-29)?
CJC-1295 No DAC dosing protocol centers on Modified GRF 1-29, a short-acting GHRH analog widely used in peptide research for pulsatile GH stimulation. Unlike CJC-1295 with DAC, this version lacks the albumin-binding Drug Affinity Complex and therefore clears rapidly.
CJC-1295 No DAC is a truncated endogenous GHRH analog with four stabilizing substitutions (D-Ala2, Gln8, Ala15, Leu27) that improve resistance to DPP-IV degradation. These substitutions extend functional activity relative to native GHRH while preserving a short pulse window.
The short half-life is often considered a feature rather than a limitation: it supports discrete GH pulses and easier titration, with rapid resolution if side effects occur.
CJC-1295 No DAC is frequently paired with Ipamorelin because the peptides target complementary pathways (GHRH receptor plus ghrelin receptor), producing synergistic GH release in research protocols.
This compound is not FDA-approved and has no active clinical development pathway. All information on this page is educational and research-reference only.
How CJC-1295 No DAC Works: Pulsatile GHRH Receptor Activation
CJC-1295 No DAC stimulates endogenous GH through direct pituitary GHRH receptor signaling with short-duration exposure.
GHRH Receptor Binding
CJC-1295 No DAC binds GHRH receptors on pituitary somatotrophs, activating cAMP pathways that trigger GH synthesis and release. Its amino acid substitutions improve stability against DPP-IV cleavage.
Pulsatile GH Pattern
With approximately 30-minute half-life, each dose acts as a discrete secretagogue pulse. This pattern is often preferred over sustained exposure because it aligns more closely with physiological GH rhythm.
IGF-1 Pathway
Each GH pulse supports downstream hepatic IGF-1 production. Repeated daily dosing can produce sustained protocol-level IGF-1 elevation while maintaining pulse dynamics per dose event.
Synergy with GHRPs
GHRH analogs and GHRPs work through separate receptors. Pairing CJC-1295 No DAC with Ipamorelin is common because combined signaling can produce stronger GH output than either pathway alone.
In practical protocol design, timing and fasting windows are emphasized to preserve pulse quality and reduce insulin-mediated blunting.
CJC-1295 No DAC Dosing Protocol & Titration Schedule
Initiation
Weeks 1-2
100 mcg once daily
Start before bed while fasted to assess response and tolerance.
Early Escalation
Weeks 3-4
150 mcg once daily
Increase by 50 mcg if initiation range is tolerated.
Therapeutic Range
Weeks 5-8
200 mcg once daily
Common maintenance level in community protocols.
Advanced Dose
Weeks 5-12+
200-300 mcg, 1-2x daily
Split timing often uses morning fasted and pre-bed dosing windows.
Maximum Community Range
Protocol dependent
Up to 300 mcg, up to 3x daily
Higher single doses can increase side effects without proportional GH benefit.
Important Titration Notes
Saturation concept: Common protocol references cite around 100 mcg as a practical per-dose saturation threshold for many users.
Dose flexibility: 5-on/2-off schedules are common for receptor sensitivity management; others run daily blocks for 8-12 weeks.
Missed dose: Skip and resume schedule; do not double-dose. Short half-life means each dose is largely independent.
Timing matters: Dose in a fasted window (typically >=2 hours post-meal). Pre-bed dosing is prioritized for nocturnal GH pulse overlap.
Cycle length: Typical cycles are 8-12 weeks followed by 4-6 weeks off.
CJC-1295 No DAC Reconstitution Guide
Vial Size: 2mg
BAC Water: 1.0 mL
Concentration: 2,000 mcg/mL
100 mcg: 0.05 mL (5 units)
150 mcg: 0.075 mL (7.5 units)
200 mcg: 0.10 mL (10 units)
300 mcg: 0.15 mL (15 units)
Vial Size: 2mg
BAC Water: 2.0 mL
Concentration: 1,000 mcg/mL
100 mcg: 0.10 mL (10 units)
150 mcg: 0.15 mL (15 units)
200 mcg: 0.20 mL (20 units)
300 mcg: 0.30 mL (30 units)
Vial Size: 5mg
BAC Water: 2.0 mL
Concentration: 2,500 mcg/mL
100 mcg: 0.04 mL (4 units)
150 mcg: 0.06 mL (6 units)
200 mcg: 0.08 mL (8 units)
300 mcg: 0.12 mL (12 units)
Vial Size: 5mg
BAC Water: 3.0 mL
Concentration: 1,667 mcg/mL
100 mcg: 0.06 mL (6 units)
150 mcg: 0.09 mL (9 units)
200 mcg: 0.12 mL (12 units)
300 mcg: 0.18 mL (18 units)
Vial Size: 5mg
BAC Water: 5.0 mL
Concentration: 1,000 mcg/mL
100 mcg: 0.10 mL (10 units)
150 mcg: 0.15 mL (15 units)
200 mcg: 0.20 mL (20 units)
300 mcg: 0.30 mL (30 units)
Step-by-Step Reconstitution Instructions
- Gather supplies: CJC-1295 No DAC vial, bacteriostatic water, alcohol swabs, and U-100 insulin syringe.
- Clean vial stoppers with separate swabs and allow to dry.
- Draw planned BAC water volume.
- Inject slowly down vial wall, not onto powder.
- Gently swirl or roll vial; do not shake.
- Confirm clear/colorless solution without particles.
- Label concentration/date, refrigerate at 2-8C, and use within 2-4 weeks.
CJC-1295 No DAC Side Effects - What Clinical and Community Data Show
CJC-1295 No DAC is generally considered better tolerated for rapid titration because of short half-life and fast clearance.
Common effects: Transient flushing, mild injection-site reactions, headache, and occasional water retention are most often reported.
Dose-dependent pattern: Higher per-injection doses tend to produce more flushing/headache without linear GH benefit in many users.
Resolution window: Most adverse effects resolve within 30-60 minutes, a key contrast versus long-acting DAC exposure.
Cardiovascular context: Published cardiovascular signal concerns are tied to DAC Phase 2 data, not specific No DAC trial datasets.
Contraindication context: Protocols typically exclude active cancer, meaningful cardiovascular disease, glucose dysregulation, pregnancy, and peptide hypersensitivity.
CJC-1295 No DAC Clinical Trial Results
Teichman et al. 2006 (JCEM)
Phase 1 (CJC-1295 parent compound) • 28/49 day protocols
Healthy adults
CJC-1295 core sequence showed robust GH/IGF-1 activation with favorable short-term tolerability context.
Ionescu and Frohman 2006 (JCEM)
Phase 1 • Single dose overnight PK
Healthy men
Preserved pulsatile GH secretion under CJC-1295 stimulation framework.
Alba et al. 2006
Preclinical • 5 weeks
GHRH knockout mice
Daily CJC-1295 normalized growth/body composition metrics.
ConjuChem Phase 2 2006
Phase 2 (DAC trial) • 12 weeks halted
192 HIV patients
Halted after a participant MI event deemed unrelated by attending physician; development discontinued.
Sackmann-Sala et al. 2009
Follow-up • -
Normal adults
Serum protein profile changes consistent with GH/IGF-1 axis activation.
No DAC-specific large registered outcome trial program is available. Current protocol logic is derived from core CJC-1295 clinical pharmacology plus mechanistic extrapolation for the short-acting non-DAC variant.
Storage & Handling
Lyophilized (powder)
-20C (-4F) or below
12-24+ months
Lyophilized (powder)
2-8C (36-46F)
Several months
Lyophilized (powder)
Room temperature
Weeks (shipping window)
Reconstituted
2-8C (36-46F)
2-4 weeks
Reconstituted (frozen aliquots)
-20C (-4F)
3-4 months
Protect from light, avoid repeated freeze-thaw cycles, and discard cloudy/discolored solutions. Use bacteriostatic water for multi-dose vial workflows.
CJC-1295 No DAC vs. CJC-1295 DAC vs. Sermorelin vs. Ipamorelin
Peptide Class
CJC-1295 No DAC: GHRH Analog
CJC-1295 with DAC: GHRH Analog (albumin-binding)
Sermorelin: GHRH Analog
Ipamorelin: GHRP (ghrelin mimetic)
Half-Life
CJC-1295 No DAC: ~30 minutes
CJC-1295 with DAC: 6-8 days
Sermorelin: 10-20 minutes
Ipamorelin: ~2 hours
Dosing Frequency
CJC-1295 No DAC: 1-3x daily
CJC-1295 with DAC: 1-2x weekly
Sermorelin: 1-2x daily
Ipamorelin: 1-3x daily
Dose Range
CJC-1295 No DAC: 100-300 mcg/injection
CJC-1295 with DAC: 1,000-2,000 mcg/week
Sermorelin: 100-500 mcg/injection
Ipamorelin: 100-300 mcg/injection
GH Release Pattern
CJC-1295 No DAC: Pulsatile (physiological)
CJC-1295 with DAC: Sustained elevation
Sermorelin: Pulsatile
Ipamorelin: Pulsatile brief pulse
FDA Status
CJC-1295 No DAC: Not approved
CJC-1295 with DAC: Not approved
Sermorelin: Formerly approved; discontinued by manufacturer
Ipamorelin: Not approved
Unique Advantage
CJC-1295 No DAC: Best pulsatile GHRH mimic and easy titration
CJC-1295 with DAC: Convenient weekly dosing
Sermorelin: Longest medical track record
Ipamorelin: Selective GH pulse without cortisol/prolactin rise
No DAC and Sermorelin are both GHRH analogs, but No DAC has longer short-acting exposure than Sermorelin and is often favored in research stacks.
DAC is more convenient but less physiologically pulsatile. Ipamorelin complements No DAC via a separate receptor pathway.
Reconstitution math differs across compounds; use calculator support for concentration-specific dosing.
See the CJC-1295 with DAC, Sermorelin and Ipamorelin for compound-specific guides.
CJC-1295 No DAC Stacking Protocols
Stack 1
CJC-1295 No DAC + Ipamorelin (GH Optimization Stack)
CJC-1295 No DAC (100-200 mcg) plus Ipamorelin (100-200 mcg).
Rationale: complementary GHRH + ghrelin receptor activation for synergistic GH release with low cortisol/prolactin impact.
View stack protocolStack 2
CJC-1295 No DAC + Ipamorelin + GHRP-6 (Advanced GH Stack)
CJC-1295 No DAC (100 mcg) + Ipamorelin (100 mcg) + GHRP-6 (100 mcg).
Rationale: broader ghrelin-pathway reinforcement layered on core GHRH stimulation.
View stack protocolStack 3
CJC-1295 No DAC + BPC-157 + TB-500 (Recovery Stack)
CJC-1295 No DAC (100-200 mcg) + BPC-157 (250-500 mcg) + TB-500 (2-5 mg twice weekly).
Rationale: systemic GH/IGF support combined with tissue-repair-focused peptides.
View stack protocolFrequently Asked Questions - CJC-1295 No DAC
Q1: What is the starting dose of CJC-1295 No DAC?
A common starting dose is 100 mcg once daily before bed in a fasted window. Many protocols increase by 50 mcg every 1-2 weeks toward a 200 mcg daily maintenance range.
Q2: What is CJC-1295 No DAC's half-life?
Approximate half-life is around 30 minutes. This supports a pulsatile GH pattern and faster washout than DAC variants.
Q3: What results can be expected from CJC-1295 No DAC?
Protocols generally target GH/IGF-1 support for recovery, body composition, sleep quality, and connective-tissue signaling. Visible composition changes are typically evaluated over 8-12 week blocks.
Q4: How do you reconstitute CJC-1295 No DAC?
For a 5mg vial, 3.0 mL BAC water yields about 1,667 mcg/mL where 12 units is roughly 200 mcg. Inject diluent slowly down the vial wall, gently swirl, and avoid shaking. Calculator: https://www.peppal.app/calculator
Q5: Is CJC-1295 No DAC FDA-approved?
No. CJC-1295 No DAC (Mod GRF 1-29) is not FDA-approved and remains an unregulated research compound.
Q6: What are the most common side effects?
Commonly reported effects include flushing, mild injection-site irritation, headache, and mild fluid retention. These are often transient and dose-dependent.
Q7: How does CJC-1295 No DAC compare to CJC-1295 with DAC?
No DAC is short-acting (~30 minutes) and usually dosed daily for pulsatile release. DAC is long-acting (6-8 days) and usually dosed weekly with more sustained exposure.
Q8: What vial sizes are available for CJC-1295 No DAC?
Most commonly 2mg and 5mg vials. Five-milligram formats are often used for longer protocol windows and cleaner per-dose economics.
Q9: How much bacteriostatic water should be added to CJC-1295 No DAC?
Typical setups are 2mg vials with 1.0-2.0 mL and 5mg vials with 2.0-5.0 mL BAC water. Pick concentration based on clean syringe-unit conversion. Calculator: https://www.peppal.app/calculator
Q10: What is the maximum dose of CJC-1295 No DAC studied?
Community upper ranges are often 300 mcg per injection up to 3x/day, but many protocols prefer lower per-dose ranges and use frequency rather than high single dosing.
Q11: How should reconstituted CJC-1295 No DAC be stored?
Store at 2-8C and generally use within 2-4 weeks. For longer storage use frozen single-use aliquots and avoid repeated freeze-thaw cycles.
Q12: What clinical trials have been conducted on CJC-1295?
Published human RCT data primarily comes from 2006 CJC-1295 studies, including Phase 1 efficacy/safety and pulsatility analyses, plus a halted Phase 2 HIV trial (NCT00267527).
Sources & Research
- Teichman SL, Neale A, Lawrence B, et al. "Prolonged Stimulation of GH and IGF-1 Secretion by CJC-1295 in Healthy Adults." Journal of Clinical Endocrinology and Metabolism, 2006 DOI: 10.1210/jc.2005-1536.
- Ionescu M, Frohman LA. "Pulsatile Secretion of GH Persists during Continuous Stimulation by CJC-1295." Journal of Clinical Endocrinology and Metabolism, 2006 DOI: 10.1210/jc.2006-1702.
- Alba M, Fintini D, Sagazio A, et al. "Once-daily CJC-1295 normalizes growth in GHRH knockout mouse." Am J Physiol Endocrinol Metab, 2006 DOI: 10.1152/ajpendo.00201.2006.
- Jette L, Leger R, Thibaudeau K, et al. "Identification of CJC-1295 as a Long-Lasting GRF Analog." Endocrinology, 2005 DOI: 10.1210/en.2004-1286.
- Sackmann-Sala L, Ding J, Frohman LA, Kopchick JJ. "GH/IGF-1 axis activation by CJC-1295 and serum protein changes." Growth Hormone and IGF Research, 2009 DOI: 10.1016/j.ghir.2009.03.001.
- Clemmons DR. "Long-Acting Forms of GHRH and GH: Effects in Normal Volunteers and Adults with GHD." Hormone Research, 2007 DOI: 10.1159/000110620.
- Henninge J, et al. "Identification of CJC-1295 in an unknown pharmaceutical preparation." Drug Testing and Analysis, 2010 DOI: 10.1002/dta.233.
- ClinicalTrials.gov — (NCT00267527).
- Aidsmap - Lipodystrophy study halted after patient death. Link.
- Wikipedia - CJC-1295. Link.
Related Protocols
6-8 days
CJC-1295 with DAC
GH Secretagogue (GHRH Analog)
View protocol~2 hours
Ipamorelin
GH Secretagogue (GHRP)
View protocol10-20 min
Sermorelin
GH Secretagogue (GHRH Analog)
View protocol~26 min
Tesamorelin
GH Secretagogue (GHRH Analog)
View protocol~20 min
GHRP-6
GH Secretagogue (GHRP)
View protocol~30 min
GHRP-2
GH Secretagogue (GHRP)
View protocolDisclaimer & Affiliate Disclosure
Disclaimer: The information on this page is for educational and research reference purposes only. CJC-1295 No DAC (Modified GRF 1-29) is an unregulated research compound not approved by the FDA for human use. No compounds discussed on this site are intended for human consumption. This is not medical advice. Consult a qualified healthcare professional before considering any peptide protocol.
Affiliate Disclosure: This site contains affiliate links to vetted peptide suppliers. We may earn a commission at no extra cost to you. Our protocol content and editorial ratings are independent of affiliate relationships.